Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)

被引:19
|
作者
Caslake, Muriel J. [1 ]
Packard, Chris J.
Robertson, Michele [2 ]
Cooney, Josephine
Nelson, Jeanenne J. [3 ]
Ford, Ian [2 ]
Gaw, Allan [4 ]
Jukema, J. Wouter [5 ]
Macfarlane, Peter W.
Stott, David J.
Shepherd, James
机构
[1] Univ Glasgow, Western Infirm Glasgow, Vasc Biochem Grp, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland
[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow G11 6NT, Lanark, Scotland
[3] GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC USA
[4] NHS Greater Glasgow & Clyde, Glasgow Clin Res Facil, Glasgow, Lanark, Scotland
[5] Leiden Univ, Dept Cardiol, Med Ctr, Leiden, Netherlands
关键词
Lipoprotein-associated phospholipids A(2); Elderly; Prosper; Inflammatory markers; Coronary heart disease risk; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; MIDDLE-AGED MEN; ATHEROSCLEROSIS RISK; ISCHEMIC-STROKE; PREDICTION; EVENTS; MARKERS; WOMEN;
D O I
10.1016/j.atherosclerosis.2009.10.041
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an inflammatory biomarker that circulates mainly bound to LDL. We evaluated the association of Lp-PLA(2) with vascular events in the elderly where the importance of LDL is diminished as a risk factor for coronary disease. Methods: Mass and activity of Lp-PLA(2) were related to risk over 3.2 years for vascular events (definite or suspected death from CHD, non-fatal MI, fatal or non-fatal stroke) in the 2804 men and 3000 women age 70-82 years in the Prospective Study of Pravastatin in the Elderly (PROSPER). Results: Lp-PLA(2) showed a moderate, positive association with risk of a vascular event with hazard ratios of 1.25 (confidence interval (CI) 1.02-1.54) for mass and 1.39 (CI 1.14-1.70) for activity for top versus bottom quartile. Risk associations were attenuated when classical risk factors, lipids and in. ammatory markers - C-reactive protein and white cell count - were included in the models. Lp-PLA(2) was unrelated to stroke risk. Inclusion of all three in. ammatory markers in multivariate models negated the association of HDL cholesterol with risk (hazard ratio 0.98; CI 0.88-1.10) and increased prediction of coronary events; the C statistic rose from 63.2% to 64.4% (P < 0.001). Conclusion: In elderly people Lp-PLA(2), alongside other inflammatory indices, is a potential biomarker for vascular events, particularly CHD. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 50 条
  • [31] Lipoprotein-associated phospholipase A2 and cardiovascular disease: Results from the Cardiovascular Health Study
    Jenny, NS
    Solomon, C
    Cushman, M
    Nelson, JJ
    Tracy, RP
    Psaty, BM
    Furberg, CD
    CIRCULATION, 2006, 113 (08) : E332 - E332
  • [32] The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with coronary heart disease or risk equivalent
    Mohler, Emile R., III
    Ballantyne, Christie
    Davidson, Michael
    Hanefeld, Markolf
    Ruilope, Luis
    Johnson, Joel
    Zalewski, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A280 - A280
  • [33] Lipoprotein-associated Phospholipase A2 is Associated with Angiographic Coronary Artery Disease and Coronary Artery Risk Factors in the Elderly
    Dong, Lini
    Qu, Xiaobing
    Hu, Zhi Gao
    Peng, Xiaoli
    Wang, Yanjiao
    Miao, Qin
    Zhang, Xiangyu
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2015, 9 (02) : 82 - 86
  • [34] The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Shepherd, J
    Blauw, GJ
    Murphy, MB
    Cobbe, SM
    Bollen, ELEM
    Buckley, BM
    Ford, I
    Jukema, JW
    Hyland, M
    Gaw, A
    Lagaay, AM
    Perry, IJ
    Macfarlane, PW
    Meinders, AE
    Sweeney, BJ
    Packard, CJ
    Westendorp, RGJ
    Twomey, C
    Scott, DJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (10): : 1192 - 1197
  • [35] Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort:: The Cardiovascular Health Study
    Furberg, Curt D.
    Nelson, Jeanenne J.
    Solomon, Cam
    Cushman, Mary
    Jenny, Nancy Swords
    Psaty, Bruce M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (05) : 792 - 799
  • [36] Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson's Disease
    Wu, Zubo
    Wu, Suyuan
    Liang, Tao
    Wang, Lin
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [37] The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review
    Reddy, Kota J.
    Singh, Manmeet
    Bangit, Joey R.
    Batsell, Richard R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2009, 3 (02) : 85 - 93
  • [38] Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER)
    Gaw, A
    Murray, HM
    Brown, EA
    ATHEROSCLEROSIS, 2005, 180 (02) : 381 - 388
  • [39] Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study
    Nelson, T. L.
    Kamineni, A.
    Psaty, B.
    Cushman, M.
    Jenny, N. S.
    Hokanson, J.
    Furberg, C.
    Mukamal, K. J.
    DIABETOLOGIA, 2011, 54 (02) : 329 - 333
  • [40] Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study
    T. L. Nelson
    A. Kamineni
    B. Psaty
    M. Cushman
    N. S. Jenny
    J. Hokanson
    C. Furberg
    K. J. Mukamal
    Diabetologia, 2011, 54 : 329 - 333